IGC vs NEPH
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
IGC Pharma exhibits severe financial distress, anchored by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from catastrophic operating margins (-1517.80%) and a significant year-over-year revenue decline of 53.60%. While the balance sheet shows low debt, the valuation is disconnected from fundamentals with a Price/Sales ratio of 28.60. Despite a speculative analyst target price of $4.12, the historical earnings track record and bearish technical trend suggest a high risk of capital loss.
NEPH presents a contradictory profile with a stable Piotroski F-Score of 4/9 and a very strong balance sheet, yet it is fundamentally overvalued. The current price of $2.88 significantly exceeds both the Graham Number ($1.54) and the Intrinsic Value ($0.77), suggesting a speculative premium. While revenue growth remains positive at 22.2%, the catastrophic collapse in earnings growth (-82.40% YoY) and a bearish technical trend (0/100) outweigh the analyst target of $7.00.
Compare Another Pair
Related Comparisons
IGC vs NEPH: Head-to-Head Comparison
This page compares IGC Pharma, Inc. (IGC) and Nephros, Inc. (NEPH) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.